Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Niagen Bioscience ( (NAGE) ) has issued an announcement.
On February 24, 2026, Niagen Bioscience’s subsidiaries ChromaDex, Inc. and ChromaDex Analytics, Inc. completed an all-cash sale of substantially all assets of their analytical reference standards and services business to VHG Labs, part of LGC Group. The transaction included a transition services agreement under which Niagen will provide operational and administrative support to the buyer for up to six months post-closing in exchange for a service fee recognized as services are performed.
The divestiture advances Niagen Bioscience’s previously announced strategy to exit non-core activities and concentrate capital and talent on its NAD+ science platform, intellectual property, and commercial growth in the longevity industry. By shedding the ChromaDex reference standards unit and aligning with LGC’s broader diagnostics and analytical solutions footprint, Niagen aims to simplify its operating structure and sharpen its focus on higher-impact, NAD+-driven revenue opportunities for shareholders.
The most recent analyst rating on (NAGE) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
The score is driven primarily by strong financial performance (profitability, low leverage, and accelerating cash flow) and a solid earnings update with raised growth guidance. Offsetting factors include weak technical trend signals (below major moving averages and negative MACD) and a moderately elevated P/E with no dividend yield data to support valuation.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a life sciences company positioned as a global leader in NAD+ science and healthy-aging research, focused on extending healthspan through NAD+-boosting solutions. Its clinically proven, patented Niagen brand of nicotinamide riboside underpins consumer supplement Tru Niagen and the Niagen Plus line of intravenous and injectable products, targeting the growing longevity and wellness markets.
The company collaborates with leading academic and research institutions worldwide and operates with state-of-the-art laboratory and quality protocols to support its NAD+ platform. Its business model is anchored in a robust patent portfolio covering NR and other NAD+ precursors, and a commercial strategy spanning direct-to-consumer supplements, clinical channels, and pharmaceutical-grade compounded products in the United States.
Average Trading Volume: 814,315
Technical Sentiment Signal: Hold
Current Market Cap: $407.8M
Find detailed analytics on NAGE stock on TipRanks’ Stock Analysis page.